Source: Annual Congress 2012 - Treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Ferreira, L. Fernandes, A. Figueiredo, F. Barata (Coimbra, Portugal). Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC). Eur Respir J 2012; 40: Suppl. 56, 2917

Member's Comments

No comment yet.

Related content which might interest you: Chemotherapy in advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 271–283 Year: 2009 Second-line therapy in elderly patients with advanced nonsmall cell lung cancer Source: Eur Respir J 2014; 43: 240-249 Year: 2004 First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009 Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017 Year: 2018 Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003 Neoadjuvant and adjuvant treatment for operable nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 244–259 Year: 2009 Treatment of advanced non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Radiotherapy in the treatment of nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 207–243 Year: 2009 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2011; 39: 172-179 Year: 2012 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2012; 39: 172-179 Year: 2012 Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Second-line weekly docetaxel in advanced non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease. Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009